Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2021

View Archived Issues

Seletalisib shows trend towards clinical improvement in patients with primary Sjogren's syndrome

FN-EDA transgenic mice developed as a new model of glaucoma

Akouos develops VEGF gene therapy for the treatment of vestibular schwannoma

Platelet complement and innate immune system proteins elevated in age-related macular degeneration

AEterna Zentaris and University of Queensland initiate development of macimorelin for ALS

THCVHS shows superior IOP-lowering activity compared to glaucoma standard of care in vivo

Delaying the second dose of Pfizer vaccine from 3 to 12 weeks boosts immune response

FDA approves IND for phase II study of ketamine in patients with LID-PD

BeiGene discloses Bcl-2 inhibitors

BroadenBio presents FGFR4 inhibitors

Chromosomal fusion - an ALTernative tumor target for PARP inhibitors?

Interim phase I data for scAAV-2.5-IL1R as local gene therapy in OA of the knee

Rodin Therapeutics identifies new HDAC inhibitors

Accent Therapeutics presents METTL3 inhibitors

Ono Pharmaceutical and The Vanderbilt University divulge potassium channel modulators

Promising effect of oral TRPC6 inhibitor BI-749327 on pulmonary hypertension

Data presented from low-dose cohort of first-in-human trial FX-201

Unity opens enrollment in phase IIa study of UBX-1325 in DME

Antibody-cytokine chimera shows promise in vivo for melanoma

Camostat mesylate does not lead to significant improvement in patients hospitalized with COVID-19

New phase Ib/IIa study evaluates VB-119 in membranous nephropathy

Further data reported from MATINS study of bexmarilimab in solid tumors

BerGenBio reports phase II topline data on bemcentinib in hospitalized COVID-19 patients

Celltrion's CT-P59 demonstrates neutralizing capability against SARS-CoV-2 variants

Promising interim phase II data released on Medicago's adjuvanted COVID-19 vaccine candidate

PYC reports efficacy data from ADOA program in patient cell models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...